• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Hershberg Robert sold $402,270 worth of shares (53,000 units at $7.59), decreasing direct ownership by 43% to 69,690 units (SEC Form 4)

    3/12/25 7:48:40 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADPT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    HERSHBERG ROBERT

    (Last) (First) (Middle)
    C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
    1165 EASTLAKE AVENUE EAST

    (Street)
    SEATTLE WA 98109

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Adaptive Biotechnologies Corp [ ADPT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/12/2025 S 53,000 D $7.59 69,690 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Robert Hershberg by Kyle Piskel, Attorney-in-Fact 03/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ADPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADPT

    DatePrice TargetRatingAnalyst
    3/21/2025$9.00Neutral → Buy
    Goldman
    7/5/2023$15.00Overweight
    JP Morgan
    1/5/2023$15.00Sector Outperform
    Scotiabank
    12/21/2022$7.50 → $14.00Neutral → Overweight
    Piper Sandler
    8/25/2022$8.00Underperform
    Credit Suisse
    6/3/2022$7.50Neutral
    Piper Sandler
    2/16/2022$40.00 → $32.00Buy
    BofA Securities
    2/16/2022$75.00 → $50.00Overweight
    JP Morgan
    More analyst ratings

    $ADPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. "We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This performance highlights the scalability of our MRD business and the growing momentum behind it. As a resul

      5/1/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours

      4/10/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

      SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostic Services Program (MolDX), has expanded coverage of clonoSEQ® to include single time point testing to monitor for recurrence in patients with a history of mantle cell lymphoma (MCL). This expanded coverage is in addition to the existing Medicare episode payment structure for clonoS

      4/8/25 8:00:00 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adaptive Biotechnologies upgraded by Goldman with a new price target

      Goldman upgraded Adaptive Biotechnologies from Neutral to Buy and set a new price target of $9.00

      3/21/25 8:00:43 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on Adaptive Biotechnologies with a new price target

      JP Morgan resumed coverage of Adaptive Biotechnologies with a rating of Overweight and set a new price target of $15.00

      7/5/23 7:14:22 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Adaptive Biotechnologies with a new price target

      Scotiabank initiated coverage of Adaptive Biotechnologies with a rating of Sector Outperform and set a new price target of $15.00

      1/5/23 7:29:02 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Financials

    Live finance-specific insights

    See more
    • Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. "We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This performance highlights the scalability of our MRD business and the growing momentum behind it. As a resul

      5/1/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours

      4/10/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

      SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. "2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements in our Immune Medicine programs. Our MRD revenue grew by 42%, with a 35% increase in clonoSEQ test volume, and we nominated a lead autoimmune indication within our Immune Medicine business," said Chad

      2/11/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Adaptive Biotechnologies Corporation

      10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)

      5/1/25 4:30:23 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)

      5/1/25 4:15:13 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Adaptive Biotechnologies Corporation

      DEFA14A - Adaptive Biotechnologies Corp (0001478320) (Filer)

      4/29/25 4:07:22 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Piskel Kyle sold $17,149 worth of shares (1,929 units at $8.89), decreasing direct ownership by 0.71% to 269,581 units (SEC Form 4)

      4/A - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/20/25 7:46:28 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Piskel Kyle was granted 7,815 shares and sold $17,149 worth of shares (1,929 units at $8.89), increasing direct ownership by 2% to 277,396 units (SEC Form 4)

      4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/19/25 7:59:39 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Robins Harlan S exercised 68,412 shares at a strike of $6.32 and sold $502,828 worth of shares (68,412 units at $7.35) (SEC Form 4)

      4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/5/25 5:27:53 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

      For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

      3/5/21 10:37:33 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

      SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. "Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medic

      3/9/22 7:00:00 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

      SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health. "Adaptive has set the stage for commercial success with well-defined growth strategies and a solid pipeline for our current research and diagnostic products. Nit

      8/4/21 4:15:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

      SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/13/24 4:30:24 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

      SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/13/24 9:00:21 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

      SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/12/24 1:30:57 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care